Research progress on fatty acid metabolism reprogramming in diffuse large B-cell lymphoma

doi:10.16352/j.issn.1001-6325.2026.04.0582

Abstract

Abstract: Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin lymphoma, and its progression is closely linked to the tumor microenvironment. Fatty acid metabolic reprogramming is one of the core aspects of tumor metabolic reprogramming. In DLBCL, abnormal regulation of fatty acid synthesis, uptake, and β-oxidation not only provides energy and structural materials for rapid tumor cell proliferation, but also influences disease initiation and progression by regulating signaling pathways and epigenetic modifications. This article reviews the roles of fatty acid metabolic enzymes, signaling pathways, and the microenvironment, and explores potential diagnostic biomarkers or therapeutic targets, aiming to provide new insights for elucidating molecular mechanisms underlying DLBCL development and advancing precise therapy.

Key words: diffuse large B-cell lymphoma, fatty acid metabolism reprogramming, tumor metabolism, tumor microenvironment, therapeutic targets

CLC Number:

R733.4

LIU Jingjing, LI Yan. Research progress on fatty acid metabolism reprogramming in diffuse large B-cell lymphoma[J]. Basic & Clinical Medicine, 2026, 46(4): 582-586.

References

[1] Cho Y,Lee J,Han B, et al. Tumor-infiltrating T lymphocytes evaluated using digital image analysis predict the prognosis of patients with diffuse large B-cell lymphoma[J]. J Pathol Transl Med,2024,58:12-21.
[2] Shi H, Pan Y, Xiang G, et al. A novel NET-related gene signature for predicting DLBCL prognosis[J].J Transl Med,2023,21:630.doi: 10.1186/s12967-023-04494-9.
[3] Zheng Y, Xu R, Chen X, et al. Metabolic gatekeepers: harnessing tumor-derived metabolites to optimize T cell-based immunotherapy efficacy in the tumor microenvironment[J]. Cell Death Dis, 2024,15:775.doi: 10.1186/s12967-023-04494-9.
[4] Elia I, Haigis MC. Metabolites and the tumour microenvironment:from cellular mechanisms to systemic metabolism[J].Nat Metab,2021,3:21-32.
[5] Kai Y, Xiaokun W, Chenghu S, et al. The role of lipid metabolic reprogramming in tumor microenvironment[J]. Theranostics, 2023,13:1774-1808.
[6] Dong C, Zhang Y, Zeng J, et al. FUT2 promotes colorectal cancer metastasis by reprogramming fatty acid metabolism via YAP/TAZ signaling and SREBP-1[J]. Commun Biol, 2024,7:1297.doi: 10.1038/s42003-024-06993-x.
[7] Lim SA, Su W, Chapman NM, et al. Lipid metabolism in T cell signaling and function[J]. Nat Chem Biol, 2022,18:470-481.
[8] Raychaudhuri D, Singh P, Chakraborty B, et al. Histone lactylation drives CD8⁺ T cell metabolism and function[J]. Nat Immunol, 2024,25:2140-2151.
[9] Li C, Wang F, Cui L, et al. Association between abnormal lipid metabolism and tumor[J]. Front Endocrinol (Lausanne), 2023,14:1134154.doi: 10.1038/s42003-024-06993-x.
[10] Li Y, Wang L, Wang J, et al.Relationship between adipocytes and hematological tumors in the bone marrow microenvironment: a literature review[J]. Transl Cancer Res, 2024,13:5691-5701.
[11] Pera B, Krumsiek J, Assouline E S, et al. Metabolo-mic profiling reveals cellular reprogramming of B-cell lymphoma by a lysine deacetylase inhibitor through the choline pathway[J]. EBioMedicine, 2018,28:80-89.
[12] Wang X, Liu H, Fei Y, et al. Metabolic pathway-based subtyping reveals distinct microenvironmental states associated with diffuse large B-cell lymphoma outcomes[J]. Hematol Oncol, 2024,42:e3279.doi: 10.1002/hon.3279.
[13] Zhong X,Zhang W,Zhang W, et al. FASN contributes to ADM resistance of diffuse large B-cell lymphoma by inhibiting ferroptosis via nf-κB/STAT3/GPX4 axis[J]. Cancer Biol Ther,2024,25:2403197.doi: 10.1080/15384047.2024.2403197.
[14] Kapadia B, Nanaji NM, Bhalla K, et al. Fatty acid synthase induced S6Kinase facilitates USP11-eIF4B complex formation for sustained oncogenic translation in DLBCL[J]. Nat Commun, 2018,9:829.doi: 10.1038/s41467-018-03028-y.
[15] Danilova OV, Dumont LJ, Levy NB, et al. FASN and CD36 predict survival in rituximab-treated diffuse large B-cell lymphoma[J]. J Hematop, 2013,6:11-18.
[16] Meng Y, Guo D, Lin L, et al. Glycolytic enzyme PFKL governs lipolysis by promoting lipid droplet-mitochondria tethering to enhance β-oxidation and tumor cell prolifera-tion[J]. Nat Metab, 2024,6:1092-1107.
[17] Caro P, Kishan U A, Norberg E, et al. Metabolic signatures uncover distinct targets in molecular subsets of diffuse large B cell lymphoma[J]. Cancer Cell, 2012,22:547-560.
[18] 张漪蓉, 魏玮庆, 马皎, 等. 靶向SOX9调控弥漫性大B细胞淋巴瘤代谢重编程的研究[J]. 上海交通大学学报(医学版),2023,43:1236-1244.
[19] Wang X, Liu H, Fei Y, et al. Metabolic pathway-based subtyping reveals distinct microenvironmental states associated with diffuse large B-cell lymphoma outcomes[J]. Hematol Oncol, 2024,42:e3279.doi: 10.1002/hon.3279.
[20] 崔建, 陈烨, 何丽, 等. 脂肪酸代谢相关基因ACSL1在急性髓系白血病中的作用及潜在价值[J]. 癌变·畸变·突变,2024,36:298-304.
[21] Nemec R,Crosbie SM,Abramson SJ, et al. Effect of atorvastatin versus placebo on efficacy in patients with diffuse large B-cell lymphoma receiving R-CHOP[J]. Leuk Lymphoma,2024,65:1-6.
[22] Liu MK, Cheng LL, Yi HM, et al. Enhanced lipid metabolism confers the immunosuppressive tumor microenvironment in CD5-positive non-MYC/BCL2 double expressor lymphoma[J]. Front Oncol, 2022,12:885011.doi: 10.3389/fonc.2022.885011.